Affordable generic medicines available on the market just 10 years ago are disappearing and supply is too consolidated, according to new data shared today. This rapid decline and consolidation, higher in certain therapy areas such as cancer care and antibiotics, risks creating more shortages and threatens vital access for patients.
The recently published EU pharmaceutical revision aims to improve medicines affordability, accessibility, and availability in Europe. The secure supply of essential medicines is the foundation to achieve these goals.
Recent shortages of essential antibiotics in Europe have renewed the urgency to reform the pricing and industrial infrastructure for these essential medicines. The off-patent sector manufactures and supplies most antibiotics in Europe needed to control bacterial infections. Pricing policies for these antibiotics must urgently be reviewed so that they remain viable to produce and supply.
The purpose of Medicines for Europe members is to improve access to medicines and provide a better availability and supply security for European patients. However, the current situation is challenging our ability to fulfil this objective.
The Hungarian Permanent Representation to the European Union hosted the event “Sustainable ways to finance innovation” organised in collaboration with the Slovak Presidency of the Visegrad 4 Group, the Permanent Representation of the Netherlands and Medicines for Europe
The global generic medicines industry supplies most of the world’s antibiotic medicine and is aware of the surge in demand of these products that is leading to shortages. The surge is driven by an unusually high rate of respiratory conditions and infections that are occurring as we exit the most acute phase of the Covid-19 pandemic and, in many countries, an unusually high rate of respiratory conditions and infections among children.